Teclistamab in Early Myeloma Relapse: Promise and Peril
This episode explores how earlier relapse in multiple myeloma is creating a tougher treatment landscape, especially for patients already resistant to lenalidomide and anti-CD38 therapy. The hosts break down MajesTEC-9, where teclistamab delivered major efficacy gains but also brought significant infection risk, CRS, and new logistical challenges for early-relapse care.
Chapter 1
Redefining Early Relapse with Bispecific Biology
Dr. James Whitfield
We- we- we are seeing a really, uh, striking shift in how we treat multiple myeloma, but it's- it's creating a major clinical bind. Patients are relapsing earlier, and when they do, the- the cancer is already incredibly tough to treat. It's- it's what we call the double-refractory trap.
Dr. Elena Rodriguez
Right, because we are using our best tools right at the very beginning now. We- we bundle immunomodulatory drugs like lenalidomide and those anti-CD38 monoclonal antibodies—daratumumab, usually—right into the frontline treatment. So when that first relapse happens...
Dr. James Whitfield
Exactly. When they relapse, the tumor is already resistant to both of those major classes. The disease is, uh, as the NEJM editorial put it, increasingly refractory to both lenalidomide and anti-CD38 therapy. And that- that leaves clinicians with very few highly effective outpatient options.
Dr. Elena Rodriguez
Which is why there was so much, anticipation for the MajesTEC-9 trial, looking at teclistamab. Now, teclistamab is a bispecific T-cell engager. A- a BiTE antibody. I- I like to think of it as a molecular matchmaker. On one arm, it grabs CD3 on the patient's own cytotoxic T-cells, and on the other arm, it binds to BCMA—B-cell maturation antigen—on the myeloma cell.
Dr. James Whitfield
So it literally drags them together?
Dr. Elena Rodriguez
Yes! It- it forces a physical handshake. And the beautiful thing, biologically, is that it bypasses the tumor's classic trick of hiding. Usually, cancer cells downregulate MHC class I so T-cells can't "see" them. Teclistamab doesn't care. It just glues them together, and the T-cell releases its perforins and granzymes to destroy the myeloma cell directly.
Dr. James Whitfield
It's an elegant mechanism, but bringing it into early relapse is a big leap. MajesTEC-9 was a phase 3 open-label trial published in early 2026. They took 593 patients who had already gone through one to three prior lines of therapy. And- and to reflect today's reality, over 80% of these patients were already refractory to an anti-CD38 antibody. They randomized them 1:1.
Dr. Elena Rodriguez
To what exactly? What was the control?
Dr. James Whitfield
Well, investigator's choice of standard triplet or doublet regimens. So, either pomalidomide, bortezomib, and dexamethasone—what we call PVd—or carfilzomib and dexamethasone, Kd. Versus teclistamab monotherapy. So, standard of care versus this bispecific matchmaker.
Chapter 2
The Efficacy Leap and Its High Toxic Cost
Dr. Elena Rodriguez
And the results were... well, they were frankly staggering, James. At a median follow-up of 17.3 months, the estimated 18-month progression-free survival for the teclistamab group was 69.8%. Compare that to just 26.9% in the standard-of-care group. That's a- a hazard ratio for disease progression or death of 0.29.
Dr. James Whitfield
A 71% reduction in the risk of progression or death. That- that is massive for a first or second relapse. And- and the complete response rates were 65.9% for teclistamab compared to just 16.8% in the control. It- it nearly quadrupled.
Dr. Elena Rodriguez
Right. But- but, as a clinician, you look at those numbers and you think, okay, what's the catch? Because there is always a biological cost when you unleash T-cells like this.
Dr. James Whitfield
The cost is, uh, immunological depletion. BCMA is not just on myeloma cells; it is expressed on healthy plasma cells too. So, teclistamab essentially obliterates the patient's normal antibody-producing factory. In the trial, grade 3 or 4 infections occurred in 41.6% of patients in the teclistamab arm, compared to 29.0% in the control arm.
Dr. Elena Rodriguez
Almost half of them getting severe infections?
Dr. James Whitfield
Yes. And even more concerningly, the rate of fatal infections doubled. It was 5.5% in the teclistamab group versus 2.8% in the control. Most of those deaths, um, occurred within the first six months of starting treatment. That means patients need aggressive prophylactic antimicrobials, intravenous immunoglobulin—IVIG—infusions, and constant, constant vigilance.
Dr. Elena Rodriguez
And then there's the acute toxicity. With bispecifics, we worry about Cytokine Release Syndrome, CRS, and neurotoxicity, ICANS. In MajesTEC-9, 66% of the teclistamab patients experienced CRS. Granted, most were low grade, but still, you're monitoring them in a hospital. And 4.1% experienced ICANS. It- it completely changes the logistics of early relapse care.
Dr. James Whitfield
It really does. Historically, a first relapse was managed in the clinic with oral triplets. Now, we are talking about moving an intensive, potentially inpatient therapy with a heavy infection risk right up to the front of the line. Is it worth it?
Dr. Elena Rodriguez
I mean, looking at that PFS curve—69.8% versus 26.9%—it's hard to argue with the efficacy. But you're right. It- it feels like we're trading outpatient convenience and a relatively normal quality of life for a highly engineered, high-intensity hospital regimen. It's a tough sell for some patients.
Dr. James Whitfield
It's the classic oncology dilemma. We have a tool that is undeniably more effective at killing the cancer, but it demands so much more from the patient and the healthcare system. We'll have to see how clinics adapt to this. Alright, I think that covers it for today. Good chatting, Elena.
Dr. Elena Rodriguez
Yeah, talk soon, James.